Association of Beta-Blockers with Survival on Patients Presenting with ACS Treated with PCI: A Propensity Score Analysis from the BleeMACS Registry

D’Ascenzo, Fabrizio; Celentani, Dario; Brustio, Alessandro; Grosso, Alberto; Raposeiras‐Roubín, Sergio; Abu‐Assi, Emad; Henriques, José P.S.; Saucedo, Jorge; González-Juanatey, José Ramón; Wilton, Stephen B.; Kikkert, Wouter J.; Núñez‐Gil, Iván J.; Arizá-Solé, Albert; Song, Xiantao; Alexopoulos, Dimitrios; Liebetrau, Christoph; Kawaji, Tetsuma; Huczek, Zenon; Nie, Shaoping; Fujii, Toshiharu; Correia, Luis; Kawashiri, Masa‐aki; Garcı́a-Acuña, José Marı́a; Southern, Danielle; Alfonso, Emilio; Terol, Belén; Garay, Alberto; Zhang, Dongfeng; Chen, Yalei; Xanthopoulou, Ioanna; Osman, Neriman; Möllmann, Helge; Shiomi, Hiroki; Kowara, Michał; Filipiak‬, Krzysztof J.; Wang, Xiao; Yan, Yan; Fan, Jingyao; Ikari, Yuji; Nakahayshi, Takuya; Sakata, Kenji; Yamagishi, Masakazu; Kalpak, Oliver; Kedev, Saško; Moretti, Claudio; D’Amico, Maurizio; Gaïta, Fiorenzo

doi:10.1007/s40256-018-0273-4

Cited by 8 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They are widely used in stable CAD, including angina free patients 3 even though their role in improving outcomes remains uncertain. Large observational series have shown association of β-blocker use with improved outcomes in acute coronary syndromes 4–6 …”

Section: Introductionmentioning

confidence: 99%

β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study

Sorbets

Steg

Young

et al. 2019

European Heart Journal

View full text Add to dashboard Cite

Aims The effect of first-line antianginal agents, β-blockers, and calcium antagonists on clinical outcomes in stable coronary artery disease (CAD) remains uncertain. Methods and results We analysed the use of β-blockers or calcium antagonists (baseline and annually) and outcomes in 22 006 stable CAD patients (enrolled 2009–2010) followed annually to 5 years, in the CLARIFY registry (45 countries). Primary outcome was all-cause death. Secondary outcomes were cardiovascular death and the composite of cardiovascular death/non-fatal myocardial infarction (MI). After multivariable adjustment, baseline β-blocker use was not associated with lower all-cause death [1345 (7.8%) in users vs. 407 (8.4%) in non-users; hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.84–1.06; P = 0.30]; cardiovascular death [861 (5.0%) vs. 262 (5.4%); HR 0.91, 95% CI 0.79–1.05; P = 0.20]; or cardiovascular death/non-fatal MI [1272 (7.4%) vs. 340 (7.0%); HR 1.03, 95% CI 0.91–1.16; P = 0.66]. Sensitivity analyses according to β-blocker use over time and to prescribed dose produced similar results. Among prior MI patients, for those enrolled in the year following MI, baseline β-blocker use was associated with lower all-cause death [205 (7.0%) vs. 59 (10.3%); HR 0.68, 95% CI 0.50–0.91; P = 0.01]; cardiovascular death [132 (4.5%) vs. 49 (8.5%); HR 0.52, 95% CI 0.37–0.73; P = 0.0001]; and cardiovascular death/non-fatal MI [212 (7.2%) vs. 59 (10.3%); HR 0.69, 95% CI 0.52–0.93; P = 0.01]. Calcium antagonists were not associated with any difference in mortality. Conclusion In this contemporary cohort of stable CAD, β-blocker use was associated with lower 5-year mortality only in patients enrolled in the year following MI. Use of calcium antagonists was not associated with superior mortality, regardless of history of MI.

show abstract

Section: Introductionmentioning

confidence: 99%

β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study

Sorbets

Steg

Young

et al. 2019

European Heart Journal

View full text Add to dashboard Cite

show abstract

Do Patients need Lifelong β-Blockers after an Uncomplicated Myocardial Infarction?

Zeitouni¹,

Kernéis²,

Lattuca³

et al. 2019

Am J Cardiovasc Drugs

View full text Add to dashboard Cite

Influence of left ventricular systolic function on the long-term benefit of beta-blockers after ST-segment elevation myocardial infarction

Velásquez‐Rodríguez

Bruña

Vicent

et al. 2021

Revista Portuguesa de Cardiologia

View full text Add to dashboard Cite

Association of Beta-Blockers with Survival on Patients Presenting with ACS Treated with PCI: A Propensity Score Analysis from the BleeMACS Registry

Abstract: BB therapy was related to 1-year lower risk of all-cause mortality, independently from completeness of revascularization, admission diagnosis, age and ejection fraction. Randomized controlled trials for patients treated with PCI for ACS should be performed.

Cited by 8 publications

References 31 publications

β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study

β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study

Do Patients need Lifelong β-Blockers after an Uncomplicated Myocardial Infarction?

Influence of left ventricular systolic function on the long-term benefit of beta-blockers after ST-segment elevation myocardial infarction

Contact Info

Product

Resources

About